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INTRODUCTION 
 
 Alopecia is a term used to denote the loss of hair. Alopecia areata (AA) is a 
common form of hair loss seen by dermatologists and accounts for 25% of all 
alopecia cases.   
 
 The factors that activate the onset of alopecia areata and the mechanisms of 
its development are not fully understood. Circumstantial evidence suggests that 
alopecia areata is an autoimmune disease with genetic substrate. Alopecia areata 
produces marked cosmetic disability and extensive psychological morbidity. 
Diagnosis is simple but treatment is challenging and time consuming. 
 
 Though various modalities are available for the treatment of alopecia 
areata, assessment of the efficacy of a treatment must be considered with care 
because the condition is highly unpredictable in presentation, evolution, and 
response to treatment. Little data exists regarding the natural evolution of the 
condition. Hence with this in mind the following study was carried out to see the 
treatment response for various modalities for this benign condition. 
 
  
Review of Literature 
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REVIEW OF LITERATURE 
 
INTRODUCTION 
 Hair is a cutaneous appendage typical of mammalian skin1. It has no vital 
function in humans, but its psychological functions are extremely important2. Hair 
is present all over the body except over the palmo plantar skin, the distal dorsal 
aspect of the digits and muco-cutaneous junction 1. Five million hair follicles are 
there in skin and 2% of it is in scalp.  In the scalp of adults aged 20-30 years the 
density of hair on an average is 615/cm2 and this density gradually decreases to 
435cm2 by 80-90 years of age.2 
 
HAIR CYCLE2: 
 Knowledge of hair cycle is important for understanding the hair problems. 
Hair growth depends on three phases of hair cycle which includes anagen, catagen 
and telogen. The anagen which is active growth phase lasts for two to six years for 
scalp hair. This is followed by the catagen (involution phase) which takes  
1- 3weeks and the telogen (resting phase) lasts for about 3 months. 
 
 The type and length of hair depends on the anagen phase. In normal 
healthy individuals, hair sheds out after the resting phase when the new hair 
anagen growth starts (exogen). In alopecia, hair shedding occurs even before the 
anagen starts leaving the hair follicle empty (kenogen). Thus, alopecia areata is 
generally a disorder of hair cycling and is considered to be a state of kenogen. 
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ALOPECIA AREATA (AA) 
 Hippocrates first used the term alopecia (literally translated as “Fox’s 
disease”). Alopecia areata was first described by Cornelius Celsus in 30 AD. 
Sauvages coined the term AA in 17604.  It accounts for   2-3% of dermatology 
cases in UK and USA, 3.8% in China, and 0.7% in India4,5,6.  The prevalence in 
general population was around 0.1-0.2% with   lifetime risk of 1.7%6.  Both males 
and females are equally affected7, but some studies reported male 
preponderance4,6,8,9.   It can occur at any age. The youngest reported case was 4-
months-old, and the oldest was in late seventies11.  Twenty percent of cases were 
children, and 60% of AA patients had their first patch before the age of 20 years7. 
Highest prevalence was between 30-59 yrs of age10. Family history of AA were 
reported in 8.7-20% of cases4,11.   
 
SYNONYMS OF AA12 
 Fox’s disease     Porrigo decalvans 
 Alopecia circumscripto    Tinea decalvans 
 Area celsi                                   Area tonstonii 
 Jonstons alopecia                            Cazanave’s vitiligo 
 Vitiligo decalvans                               Celsus vitiligo 
 
AETIOLOGY: 
 AA accounts for about 2% of new dermatological outpatient attendance2,13. 
At present it is not possible to attribute it to any single cause. Various theories 
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such as infections, genetic, stress, trauma (physical), immunologic, endocrine 
dysfunction and focal sepsis have been proposed by earlier workers. 
 
The etiopathogenesis of AA will be discussed under following headings. 
Genetic factors 
Immunological factors 
Atopy 
Stress 
Infection 
 
GENETIC FACTORS  
 Genetic factors play an important role in the origin of AA. A positive 
family history has been found in about 8.7-20% of patients4,11. There was a 
significantly higher incidence of family history of  AA in patients with early onset 
of AA. The mode of inheritance is thought to be an autosomal dominant with 
variable penetrance. Some studies have shown a concurrence in the onset among 
twins14. AA is most likely a polygenic disease where several potentially 
identifiable major genes affect disease susceptibility and minor modifying genes 
may further affect the phenotype15. There has been increasing evidence of 
association between AA and HLA class II genes.  
 
 Studies have revealed an association with HLA-A1, HLA-B62, HLA-DR4, 
HLA-DR5, HLA-DQ1, HLA-DQ3, HLA-DR11 and HLA-DQ716. One of the 
studies has shown that 80% of all AA patients were positive for HLA-DQ3, 
suggesting that this antigen is a marker for general susceptibility to AA16,17. HLA-
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DR16 was significantly less common in patients than in control group and this 
allele probably has a protective role for AA.  
 
 Juvenile onset and severe involvement were related with CW7 and 
DR116,17. HLA-DR5 is linked to early onset form of AA and more extensive hair 
loss. The alleles DR4 and DQ7 are markers for more severe long standing 
alopecia totalis and universalis respectively18.  
 
 Recently, genome wide association studies (GWAS) identified specific 
genetic markers for AA. GWAS can recognize specific individual genes, which 
may increase the risk for AA. Petukhova et al. surveyed the entire genome and 
identified 139 single nucleotide polymorphisms (SNPs) for AA, clustered in 8 
regions of the genome. GWAS studies had found key genes in AA related to T-
cells (IL2/IL21, IL2RA, CTLA4, IKZF4, HLA) and hair follicle (NK-activating 
ligands-ULBP3, ULBP6, STX17, PRDX5)19,20. All these evidences point towards 
the genetic predisposition in the development of AA. 
 
PSEUDOHERIDITY IN AA21 
 In some familes there is an unusually high incidence of AA which may be 
due to psychological component at the background perpetuating a stressful 
environment which takes toll generation after generation. The term pseudo 
heridity describes the situation which derives from environmental rather than 
genetic factors21. There is up to 8.8 % increased frequency in polyglandular 
syndrome2,13. The increased frequency of AA in Downs syndrome and 
polyglandular syndrome is due to mutation of autosomal regulator gene on 
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chromosome 2121. Several studies have confirmed the association between AA 
and atopic state3. 
 
IMMUNOLOGICAL FACTORS: 
 The idea that AA is an autoimmune disease was suggested first by 
Rothman . The association of AA with other autoimmune diseases like thyroid 
disease, anemia, diabetes mellitus, vitiligo, and psoriasis may be one of the causes 
to believe AA is an autoimmune disease22,23. Increased level of Hair follicle-
specific antibodies, especially to keratin 16 and trichohyalin were found in 
peripheral blood of AA patients24.   
 
 Hair follicles being an immune-privileged site, major histocompatibility 
complex (MHC) class I and II molecules are not expressed. TGF- β, IGF-1, and α-
MSH are more expressed.25 This immune privilege is collapsed in AA leading to 
increased MHC I and II complexes, decreased immunosuppressive molecules and 
higher expression of adhesion molecules (ICAM-2 and ELAM-1) in perivascular 
and peribulbar hair follicular epithelium. This leads to perifollicular 
inflammation26 and thus the activity of hair follicle is adversely affected, resulting 
in thin dystrophic hair with miniaturization27.   
 
 Increased prevalence of antithyroid antibodies, thyroid microsomal 
antibodies, of gastric parietal cell antibodies as well as antinuclear and antismooth 
muscle antibodies have been reported. There have been reports of association of 
AA with pernicious anaemia, myasthenia gravis, diabetes, vitiligo,lupus 
erythromatosus, rheumatoid arthritis, ulcerative colitis, psoriasis and lichen 
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planus. Muller and Winkleman have reported an incidence of 4% of vitiligo in AA 
patients. Milgraum et. al. have found 24% of 45 children 16 years of age with AA 
to have abnormal thyroid function test or elevation of thyroid microsomal 
antibodies. 
 
 
 
HUMORAL IMMUNITY 
 Toben et. al. have found high level of antibodies to multiple structure of 
anagen hair follicle in AA patients using indirect immunoflorescence28. The most 
common target structures were the outer root sheath, followed by the matrix, inner 
root sheath and hair shaft. 
 
CELL MEDIATED IMMUNITY 
 Studies of cell-mediated immunity in AA have given conflicting results. 
Circulating total T lymphocytes are reduced or normal3,29. A slight increase in 
helper cells (CD4) and decrease in number of suppressor T cells (CD4) resulting 
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in an increase in the ratio of helper to suppressor cells correlates with the amount 
of hair loss29.  
 
 Successful treatment of AA with immunomodulatory agents such as oral 
cyclosporine and systemic steroids also supports the immune mediated 
pathogenesis in AA30,31. Biopsies of patients treated with contact allergen 
diphencyprone and minoxidil have shown reduction in peribulbar T cell, in 
regrowing AA32.  
 
 Increased frequency of organ specific antibodies, antibodies to pigmentary 
hair follicles, high level of auto antibodies to multiple structures of anagen hair 
follicles in AA patients, an increase in ratio of helper to suppressor cells, are the 
evidences to support the hypothesis that alopecia areata is a hair follicle-specific 
autoimmune disease, triggered by environmental factor in genetically susceptible 
individuals.  
 
ATOPY 
 The association between alopecia and atopy is observed in many studies. In 
atopic indivuduals, AA occurs at an earlier age and then to be more severe than in 
non-atopics. Statistical analysis in Indians with  AA showed no such links33. 
 
STRESS34 
 The influence of psychological factor in development, evolution and 
therapeutic management is well documented35. Psychological trauma is often 
suggested as a factor involved in precipitating attacks of AA. Koo et al.have 
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reported 74% of patients of AA had one or more lifetime psychiatric illnesses. 
Major depression, generalized anxiety, social phobia and paranoid disorders  were 
all present in patients with AA at rates significantly higher than in general  
population34. 
 
INFECTION 
 Focal infection , particulary dental disease has been reported as a 
precipitant in AA, but never been shown ,conclusively to  be important36. Skinner  
et. al. have shown convincing positive association with CMV33,37. Subsequent 
studies have not confirmed these findings38. 
 
 Besides these , hormones, diet,  vaccinations and many others were 
incriminated in the pathogenesis of AA27,39.  Iron deficiency was noted in 24-71% 
of females with AA40. AA was less frequently observed in people, taking diet rich 
in soy oil. Some studies found reduced zinc levels in AA patients9, but others 
reported conflicting results41.  An outbreak of AA in workers of water treatment 
plant in paper factory, linked to long-term exposure to chemical acrylamide  was  
reported by Roselino et al42.   
 
CLINICAL FEATURES1,2,3 
  AA occurs all over the world.  Both sexes are almost equally affected .The 
onset of disease occurs at any age with the peak incidence probably between the 
age of 20 and 50 yrs. In an Indian study the incidence among children was higher, 
around 31%. 
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  The characteristic lesion of AA is commonly a round or oval, totally bald, 
smooth  patch involving the scalp or any hair bearing area on  body. The hair loss 
is usually asymptomatic in most cases, but some patients complain of parasthesias 
with mild to moderate pruritis , tenderness, burning sensation or pain before the 
appearance of patches. 
                                
Clinical classification of AA 
1.Based on pattern                2.  Based on extent                     3.  Based on area 
Patchy type                            AA circumscripta                         AA of the scalp 
Reticular type                        AA subtotalis                                AA of eyelashes 
Ophiasis type                         AA totalis                                     AA of eyebrows 
Sisaipho type                         AA universalis                              AA of beard 
Diffuse type                           Diffuse AA                                   AA of body hair 
Perinevoid  type                    AA incognito                                 AA of nail 
 
 Alopecia areata – The most commonly used term covers all forms of the 
disease 
 Alopecia partialis – Defines  specific patchy hair loss 
 Alopecia totalis – Involves100 % loss of scalp hair. 
 Alopecia universalis – When all body and scalp hairs are lost 
 Alopecia areata barbae – AA lesion of beard 
 Alopecia areata ophiasis –  A special band like pattern of AA , which winds 
along the occipital hair line extending toward the temples ( oophiasis – Greek 
for snake) 
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 Diffuse AA –A term occasionally used for an alopecia areata where there is 
generalized thinning of hair of scalp. 
 Reticular alopecia areata-  Multiple active, stable or re growing patches, which 
may merge to form mosaic or reticular pattern.  
 Sisaipho AA-  Opposite of ophiasis where hairs are lost  centrally and spared 
at the margins of scalp. It may mimic androgenetic alopecia. 
 AA Incognito –  First described by Rebora in 1987. Extremely acute onset 
with subsequent diffuse hair loss that occurs within few weeks. 
 Perinevoid AA – An unusual and rare form with patches around a nevus. 
 
Ikeda classification of AA  
Based on the associated conditions and on the course of the disease 
1. Atopic type (10%):  Begins  in early life and mostly (30-75%) progresses 
to AT. 
2. Autoimmune type (5%):  Seen in middle-aged , runs prolonged course. 
Associated with autoimmune diseases, diabetes mellitus, peptic ulcer and 
progresses to AT in 10-50%. 
3. Pre hypertensive type(4%):  Occurs in young adults whose one or both 
parents were hypertensive and progress fastly to AT in 40% of cases. 
4. Common type(81%):  Mostly affects adults aged 20-40 years  and AT 
develops in 5-15% of cases. 
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 A frequent feature of an AA patch is ‘exclamation mark’ hair that may be 
present at its margin12. Exclamation mark hair denotes the broken short hairs that 
taper proximally. At the margins the normal looking hair may be easily extracted. 
This pull test when positive may indicate very active disease. 
 
 A hand lens shows that at the margin, the free ends are splayed, giving 
frayed  appearance. Even the apparently normal terminal hair, found within the 
patches, may show one or more constrictions in their shaft. 
 
 Shuster has described the coudablity sign to (differentiate diffuse AA from 
other diffuse alopecia) in AA, a normal looking hair kinks when forced inwards or 
bents, the kink being situated 5-10mms above the surface43. 
 
 An intriguing feature of AA is sparing of white hairs44. It appears 
preferentially to affect pigmented hair, so that non pigmented hair is spared.  The 
white hairs although less susceptible are not immune to the disease. 
 
The re growth of hair may be 
 Fine and un pigmented hair initially 
 Gradually gains in caliber and color 
 Heterochromia of hair45 
 Hair growth starts in center, extends peripherally 
 May remain un pigmented for a long time- leading to poliosis 
 Re growth and extension may occur simultaneously in different 
regions of the scalp 
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ASSOCIATED CLINICAL SIGNS 1,2,3 
NAIL INVOLVEMENT 
 Nail involvement may be associated with AA. The reported incidence of 
nail changes range from 10 to 66%. Changes may be seen in one ,several or all 
nails. The dystrophy may precede or coincide with AA and may also occur after 
resolution of AA , some authors speculate the possibility of ‘Twenty nail 
dystrophy sine alopecia’ 
 
 The commonest  nail change is superficial,uniform minute pits arrange 
regularly along and across the nail giving a ‘Scotch Plaid’ effect or coalescing 
into ripples.  
 
Other changes include , 
 Trachyonychia or rough nails(longitudinal striation resulting in sand 
appearance) 
 Red or mottled lunula 
 Nail thinning and ridging 
 Beau’s lines (grooves through the nails matching that of the lunula margin)  
 Onychorrhexis (Superficial splitting of nail extending to the free edge) 
 Onychomeadesis (Onycholysis with loss of nails), 
 Koilonychia punctate or transverse leuconychia  
 Dystrophy 
 splitting 
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EYE CHANGES2,46 
 Keratoconus and cataract are the most common eye changes reported in 
association with AA. Other reported eye changes include Horner’s syndrome, 
ectopia of the pupil, iris atrophy or tortuosity of the fundal vessels. 
 
ASSOCIATIONS 
 Thyroid autoimmunity 
 Vitiligo 
 Atopy 
 Down syndrome 
 Addison disease 
 Autosomal recessive autoimmune polyglandular syndrome(APS- I) 
 Pernicious anemia 
 Lupus 
 Celiac disease 
 Ulcerative colitis 
 Multiple sclerosis 
 Psychological disturbances 
 
INVESTIGATIONS : 
 Diagnosis is based mainly on the clinical appearances. AA is characterized 
by non scarring smooth bald patches. Histology can be used to corroborate the 
diagnosis. Trichogram reveals a mixed telogen dystrophic pattern. Telogen hairs 
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predominate in the slowly progressing patches, whereas dystrophic anagen hairs 
form the majority in rapidly progressing disease. 
 
 Presence of exclamatory mark hairs at periphery, positive hair pull test (>6 
hairs), daily hair count (>100 hairs), hair pluck test (more telogen hairs) and 
dermoscopy (black dots,yellow dots, brokenhair, and tapering hair) suggest active 
disease.  
 
TRICHOSCOPY 
 Trichoscopy is a non-invasive method of hair and scalp evaluation. The test 
may be performed with the use of a handheld dermoscope or a videodermoscope. 
Trichoscopy findings in 
 Alopecia Areata 
o Yellow dots (hyperkeratotic plugs),  
o Micro-exclamation mark hairs, 
o Black dots (destroyed hairs in the hair follicle opening) 
o Miniaturized nanogen hairs 
 Androgenetic alopecia  
o Greater than 20% diversity in the hair diameter  
o A brown, depressed halo at the follicular opening – Early cases 
o Yellow dots – Advanced cases 
o Honeycomb-pigmented appearance is seen in sun-exposed regions 
of the scalp.  
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 Tinea capitis 
o comma hairs, corkscrew hairs , fractured hair shafts 
 Cicatricial alopecia 
o Reveals decreased hair density and loss of follicular openings 
 Lichen planopilaris  
o Hyperkeratotic, perifollicular white scales with variable 
perifollicular erythema and peripilar white dots along with blue-gray 
dots with a target distribution around the follicle.  
 Discoid lupus erythematosus of the scalp 
o Mottled dyschromia, follicular plugs, telangiectasias, white central 
plaques, and irregularly distributed blue-gray dots in a speckled 
pattern between the hair follicles may be seen. 
o Red dots appear as erythematous,  polycyclic, concentric structures, 
regularly distributed around the follicular opening. 
 Folliculitis decalvans  
o Tufted hairs 
o Perifollicular pustules  
 
HAIR PULL TEST.  
 A group of approximately 60 hairs is hold between the thumb and index 
finger of the non dominant hand. With the dominant hand the strands of hair are 
loosely twisted to remove tray hairs and then the hairs are grasped between the 
dominant thumb and forefinger near the scalp. Gentle traction is applied in a 
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smooth, gradual manner, away from the scalp. The number and type of hairs 
extracted may give clues to the underlying diagnosis. 
 
 Grasping a few hairs from the edge of a focal area of hair loss may give an 
indication of disease activity.  
 
Telogen effluvium   - Increase in telogen hairs extracted from all  
     areas 
Alopecia areata        - Increase in telogen hairs or dystrophic anagen  
     hairs from affected areas 
Primary cicatricial alopecias -  Increase in anagen hairs extracted (pigmented  
     bulb, ensheathed within root sheath) 
Loose anagen syndrome   - Painless extraction of dysplastic anagen hairs,  
     Often lacking root sheath  
 
TRICHOGRAM. 
 A trichogram is a forced pluck of hair that includes the hair roots. A group 
of 60–80 hairs is clasped between rubber armed forceps or needle holders, close to 
the scalp surface. The examiner holds the needle holders firmly and rapidly tugs 
the needle holders away from the scalp in a perpendicular direction to extract all 
the hairs in the sample. The hairs can then be analysed under a microscope to 
calculate the percentage of hairs in telogen and anagen phases.  
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HISTOPATHOLOGY 
 The histopathological findings varies with duration of the disease. Ideal 
biopsy should include  two 4 mm punch including  the subcutaneous fat. One 
specimen is processed with vertical sectioning and other with horizontal 
sectioning. If only a single specimen is planned, horizontal sections will give a 
better . A horizontally-sectioned scalp biopsy in addition confirming the diagnosis 
of AA also provides information about the possible regrowth47. The ideal site for 
biopsy is at the advancing border of hair loss. This helps to view the follicles at 
different levels in dermis to quantify the hair follicle density, diameter, and to 
assess the proportion of hair follicles in various stages. A mean count of less than 
1follicle/mm 2  usually indicates less chances of regrowth47. 
 
 Acute stage -  Peribulbar and intra bulbar lymphocytic inflammatory 
infiltrate around anagen follicles, resembling 'swarm of bees,' is characteristic. 
The lymphocytic infiltrate  are mainly found  around the hair matrix and dermal 
papilla  sparing the bulge area, causing follicular edema, cellular necrosis, micro 
vesiculation, and pigment incontinence. A dense lymphocytic inflammation can 
cause weakening of the hair shaft resulting in a trichorrhexis nodosa-like fracture, 
leading to the exclamation mark hairs48.  
 
 Sub acute stage - High proportion of catagen/telogen hair follicles are seen.  
 
 Chronic stage - Follicular miniaturization with variable inflammatory 
infiltrate are seen in papillary dermis. The terminal to vellus hair ratio is decreased 
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to 1:1 in contrast to 7:1 in normal population. Androgenetic alopecia also shows 
follicular miniaturization, but more number of telogen hairs with decreased 
anagen to telogen ratio may be a clue towards AA47. Immunofluorescence studies 
shows deposits of C3, IgG and IgM on the basement membrane in the inferior part 
of  hair follicle. 
 
 Recovery stage - The number of terminal anagen hairs increase and there is 
a lack of inflammation. 
 
HISTOPATHOLOGICAL DIFFERENTIAL DIAGNOSIS: 
 In androgenic alopecia, dermal infiltrates when present  remains 
superficial, perivascular. Alopecia syphilitica may produce follicular infiltrates 
that can closely mimic those of acute alopecia areata. Syphilitic alopecia areata 
may demonstrate a superficial and deep perivascular  and perifollicular infiltrate 
that penetrates the outer root epithelium with a concomitant perifollicular 
fibrosing reaction.  
 
 In telogen effluvium normal number of hair follicles with no 
miniaturization of follicles and a slight decrease in the anagen to the telogen may 
be noted3. 
 
 Optical coherence tomography (OCT) is a recently evaluated non-invasive 
technique to detect the hair shaft abnormalities in AA. Bartles et al. demonstrated 
that the cross section of hairs from an AA patch was significantly lower compared 
with hairs of an unaffected area by this OCT49. Thus, OCT may be an useful non-
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invasive technique to differentiate AA from other causes of patchy alopecia, such 
as trichotillomania. 
 
 Complete hemogram, ear nose throat and dental examination are done rule 
out any foci of sepsis. In doubtful cases, Potassium hydroxide wet mount of hair 
root and fungal culture is done  to rule  out fungal infection. Serological test is 
done to rule out syphilis and lupus. Serum levels of thyroid hormones may be of 
use and may be done in suspected cases of thyroid disorders.    Thyroid screening 
may be of use in long-standing cases, females with persistent patches, patients 
with suggestive symptoms of thyroid disease and severe AA (AT/AU).  
 
SALT SCORE50 
 Severity of AA can be measured by SALT((severity of alopecia tool)  
score, developed by the National Alopecia Areata Foundation working committee.  
 
SALT score is useful to find out the quantitative assessment of scalp hair 
loss. The entire scalp was divided into 4 parts based on the surface area, top (40% 
- 0.4), posterior (24% - 0.24), right side (18% - 0.18), and left side of scalp (18% - 
0.18). Percentage of hair loss in each area is determined independently and is 
multiplied by the percentage of scalp covered in that area of the scalp, and 
summing the products of each area will give the SALT score. For example, the 
hair loss is 40%, 30%, 20% and 10% in top, back and right and left side 
respectively, then the SALT score can be calculated as- (40 × 0.4) + (30 × 0.24) + 
(20 × 0.18) + (10 × 0.18) =16 + 7.2 + 3.6 + 1.8 = 28.6. SALT score is easily 
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reproducible and validated. However, it does not include hair pigmentation, body 
hair, and nail involvement. 
 
DIFFERNTIAL DIAGNOSIS1,3 
AA has to be differentiated from the from the following conditions 
1. Telogen effluvium - Here the hair loss is generalised over the entire scalp, 
where as in AA it is usually patchy .The hairs that are shed are either in 
telogen or dystrophic anagen  in AA, but are predominantly in telogen in 
telogen effluvium. 
2. Androgenetic alopecia-It typically involves the fronto temporal region and 
the vertex 
3. Trichotillomania-Patches of alopecia with twisted broken hairs are noticed. 
4. Secondary syphilis –It is a moth eaten  alopecia with positive serological 
investigation 
5. Alopecia neoplastica51-There may be history of malignancies like 
carcinoma breast or others .The affected skin is slightly indurated and 
erythematous. A biopsy clinches the diagnosis. 
6. Congenital triangular alopecia- Characterised by a triangular area overlying 
the frontotemporal suture just inside the anterior hair line with its base 
directed forward which is completely bald or covered or by sparse vellus 
hair. 
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7. Tinea capitis- The patches of baldness of have irregular borders and broken 
bits may be seen within the patch. Examination of hair root with 40%KOH 
reveals fungal elements. 
8. Others – Congenital hypotrichosis, Ectodermal dysplasis, Loose anagen 
hair , Cicatricial alopecia, Tractional alopecia.. 
 
COURSE OF AA  
 The progress of AA is unpredictable. The initial patch may regrow within a 
few months or further patches may appear after interval of 3 to 6 weeks and 
further patches may appear in a cyclical fashion at varying intervals. A succession 
of discrete patches may rapidly become confluent by the diffuse loss of remaining 
hair. In some cases the initial hair loss is diffuse and total denudation of scalp has 
been reported. Diffuse hair loss also may occur over a part or whole of the scalp 
without the development of bald patches. Kling miller has showed that white hairs 
are spared initially by the disease process. Patients with sudden diffuse onset of 
AA would appear to ‘go white” over the course of a few days. Re-growth is often 
at first fine and unpigmented but usually the hair gradually resume its normal 
calibre and colour. Persistent depigmented hair regrowth from the site of AA has 
also been reported52. 
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PROGNOSIS 
 The prognosis is good in the common simple form of AA in which the hair 
loss is confined to the scalp and has got a high natural remission rate. 
The following are indicators of poor prognosis. 
 Early age of onset 
 Child with atopy 
 Patients with Down’s syndrome 
 Family history  of AA 
 Alopecia totalis or Alopecia Universalis 
 Involvement of more than 50% of the scalp 
 Ophiasic and reticular pattern 
 Bilateral loss of eyebrow and eyelashes 
 Severe nail changes 
 Patchy regrowth of terminal hairs within the patch 
 Recurrent episode 
 
TREATMENT1,2 
   Early recognition and intervention involving topical and or intralesional therapy 
can provide patient with comforting reassurance about eventual recovery. An 
unpredicatable course and heterogeneity of the disease leads to varying results 
being obtained with the same therapy. The various modalities can be classified as 
follows, 
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1. Topical therapy 
2. Systemic therapy 
3. Others 
 
TOPICAL THERAPY INCLUDES 
1. Immunosuppresants-   Topical corticosteroids with or without occlusion, 
intralesional steroids, nitrogen mustard. 
2. Non specific irritants- Anthralin, Phenol, Salicylic acid,  sulphur , oil of 
cade, cantharidin, croton oil, tretinoin 
3. Contact sensitizer- Dinitrocholrobenzene ,Squaric acid dibutylester 
(SADBE) and diphencyprone 
4. Photochemotherapy 
5. Cryotherapy 
6. Lasertherapy - excimer laser(308nm), pulsed infrared diode laser(904nm) 
 
SYSTEMIC THERAPY  
1. Immunosuppresants - corticosteroids, cyclosporine 
2. Immunomodulators  - alefacept 
3. Photochemotherapy -whole body  PUVA 
4. Miscellaneous -  Sulfasalazine,  IVIg 
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OTHERS 
 Psychotherapy – hypnotherapy, systemic desensitization 
 Supportive therapy – Dermatography(  tattooing) , hair pieces or wigs 
 Investigational therapy – Recombinanthuman bone morphognic protein  , 
intralesional candida antigen 
 
TOPICAL THERAPY 
 The mode of action and effects of various modalities are as follows. 
 
TOPICAL STEROIDS2,53: 
 Corticosteroids because of their anti-inflammatory action have been used 
widely in the management of alopecia areata. Topical steroids of class I to V are 
effective in Alopecia areata, but take several months for elicitation of hair growth. 
Most studies have used topical flucinolone and halcinonide. Side effects include 
acne, hypertrichosis and folliculitis ,due to inadvertent transfer from scalp. Local 
epidermal atrophy can occur when potent steroids are used. 
 
INTRALESIONAL STERIODS3,54,55  
 Intralesional steroids are considered the first line therapy for adult patients 
with less than 50% of the scalp involvement. Concentrations ranging from 2.5-
10mg/ml of Injection triamcinolone acetonide may be used. Preferred dose is 
5mg/ml (maximum volume, 3ml). It is injected intradermally with a 0.5 in long 
30gauge needle as multiple 0.ml injections at 1 cm intervals. Treatment is 
repeated every 4 to 6 weeks. Initial regrowth is often seen in 4-8 weeks. Response 
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rates up to 86% have reported. This mode of treatment is well tolerated by adults 
and the predominant side effect noticed was transient atrophy. 
 
TOPICAL IRRITANTS 
 These agents rely on the induction and maintenance of skin inflammation 
by repeated application of an irritant. 
 
ANTHRALIN3,56 : 
 Anthralin has been used in treatment of AA in concentration of 0.25% to 
1.0%.It may be have a non specific immunomodulating effect in eliciting hair 
growth. Clinical irritation is not necessary for its efficacy and short contact 
therapy is effective and cosmetically acceptable regrowth  has been reported to 
vary from 20 to25%. Anthralin 0.5% to 1% cream  may be applied overnight or as 
a short contact therapy initially for 30 minutes and gradually increased to 1 hour  
with 1% antharlin cream. When therapy is effective new hair growth is seen 
usually within 3  months. It may take 24 or more weeks for cosmetically 
acceptable response. Adverse effects include irritation, scaling, folliculitis and 
regional lymphadenopathy. Patients should be advised to protect treated area from 
sunlight, avoid getting anthralin into the eye and be warned about staining of the 
treated skin and clothes that come in contact with anthralin. 
 
PHENOL57,58 : 
 Phenol is well known as an antiseptic agent. It is also attributed to have 
antipruritic,  antibacterial (>1%), antifungal (>1.3%), and a local anaesthetic 
property. At a concentrations over 80%, phenol coagulates proteins. Pertaining to 
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its easy availability and affordability, it is being used in many office procedures in 
dermatology clinics. The mechanism of action is based on its irritating property 
that leads to tissue necrosis. A study done by siddhi chikhalkar et al on fifty 
patients treated with 88% phenol at three weekly interval showed 78% clinical 
response. 
 
CONTACT SENSITIZERS2,3,59-62 
 Topical immunotherapy is the most effective and an accepted modality in 
the treatment of AA. The mechanism of action of local sensitizers is by 
immunomodulation. There is a decrease in the peribulbar CD4/CD8 Lymphocyte 
ratio, a shift in the position of T lymphocytes away from perifollicular areas to the 
interfollicular areas and dermis. Two concepts of local immunomodulation have 
been advanvced. First being that effector T cells are attracted in that area ,there is 
probably a localised antigen competition ocuring. The second being that repeated 
application activates non specific suppressor responsible for AA. Three contact 
sensitisers have been used in AA namely dinitrocholrobenzene(DNCB), Squaric 
acid dibutyl ester (SADBE)and diphenyl cyclo propanone (DPCP).The use of 
DNCB has been discontinued because of its mutagenetic effect. 
 
 SADBE is an ideal immunogen in that it is a strong topical sensitiser ,it is 
not found in the natural environment ,does not cross react with other chemicals 
and it not mutagenic . 29% to 87% of the patients report  successful regrowth of 
hair after the use of SADBE. The disadvantage of SADBE is that is not as stable. 
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Efficacy of DPCP in the treatment of AA range from 4% to 85%. However during 
long term follow up it has been noticed that, a 3rd of the responders with 
cosmetically accepatable results eventually stop responding to the immunogen. 
Initial responses are seen 12 weeks after therapy and cosmetically acceptable 
results at 24 weeks. If there is no response by 12 weeks, DPCP topical 
immunotherapy is discontinued. DPCP is applied as 92% solution in acetone with 
a wooden applicator to a 4x4 cm area on one side of the scalp. If after 1 week 
there is no eczematous response, 0.001% solution is applied to the same half of 
the scalp. If the initial eczematous reaction is severe, treatment is delayed by 1 
week.  
 
 The aim of the treatment is to maintain a low grade tolerable erythema and 
pruritus on the treated side for 24 to 36 hours after application. The applications 
are repeated weekly and the concentrations are titrated according to the severity of 
previous weeks reactions. Concentrations used vary from 0.0001%to 2%.The 
DPCP is applied and left for 24 hours. As DPCP is degraded by light, the scalp 
should be protected from light. Once hair growth is established on one side the 
next side is treated. Untoward effects includes eczematous reactions with or 
without blistering, or extension of allergic contact dermatitis to other areas, 
itching and edema of the face and scalp, regional lymphadenopathy and post 
inflammatory hyper or hypopigmentation. Contact urticaria, vitiligo and erythema 
multiforme have also been reported. DPCP is contraindicated during pregnancy. 
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PHOTOTHERAPY63,64 
  Orally administered PUVA therapy has been one among the numerous 
available modalities in the treatment of alopecia areata. The use of Oral PUVA is 
often limited by side effects. Hence PUVA has been used topically. It has also 
been used in the form of turban, where towels soaked in 0.00001% of 8 
methoxypsoralen are wrapped around the patients head in a turban fashion,for a 
period of 20 minutes and then it was followed by PUVA radiation. 
 
 PUVA therapy results for alopecia areata are highly varied. The major 
problem with PUVA therapy is the high relapse rate. Circumscirbed lesions 
respond better than total alopecia and total body PUVA is probably more effective 
than local irradiation. Follow up studies of large group of patients have shown that 
PUVA in general is not an effective treatment option. 
 
 Phototherapy with NB UVB  have been tried in various studies. It is given 
initially thrice a week. Initial treatment dose was determined according to the skin 
phototype: 0.2J/cm2 for skin phototype II and 0.3J/cm2 for phototype III. 
Treatment continued with 20% dose increases at each subsequent session to a 
maximum of 1.8J/cm2. 
 
 The dose and frequency of treatments were gradually reduced once 
satisfactory clinical responses were achieved. The frequency was reduced to twice 
per week when terminal hair regrowth was seen with no further abnormal hair fall, 
then once per week, and finally terminated when regrowth was maintained. 
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CRYOTHERAPY65: 
 Lei et .al used a cotton swab dipped in liquid nitrogen to the patches of 
AA, for  2 freeze thaw cycles of 15 seconds each repeated  once in two weeks. 
Mechanism of action of liquid nitrogen may be due to improved blood circulation 
to the hair follicles thus promoting topical nutrition and acceleration of hair 
growth. 
 
 After initial vasoconstriction with cryotherapy, there is a significant local 
vasodilatation during the thaw period .Thus, cryotherapy is speculated to dilate 
the vessels around the affected hair follicles, with an increase in the blood flow 
leading to follicular hair regrowth. Moreover, local edema and inflammation 
occurring after cryotherapy may play a role in inducing vasodilatation. 
Cryotherapy also causes  partial damage to keratinocytes, especially the antigenic 
components of hair folliclekeratin16 and trichohyalin, which are targeted by 
antibodies and thus decreases  perifollicular infiltrate. Cryotherapy may also alter 
tissue Langerhans cells, which in turn could alter the process of antigen 
presentation with further decrease in T cell infiltration. 
 
 The adverse effects noted were insignificant and included mild swelling, 
hyperesthesia and mild itching in the treatment area for a few hours following 
treatment. Liquid nitrogen therefore was suggested as an efficient, simple, cheap 
modality of therapy without any troublesome side effects. 
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LASER THERAPY : 
 Encouraging results have been obtained with excimer laser (308 nm) and 
pulsed infrared diode laser(904 nm). 
 
OTHER TOPICAL THERAPIES 
Minoxidil66 
 Minoxidil is a powerful vasodilator.Used mainly in andrgenetic alopecia 
topically as 2%–10% solution, this drug has also been found useful in AA. 
Cosmetically acceptable regrowth was induced in 20%–60% of cases in various 
studies, higher concentrations being more effective. 
 
Tacrolimus 
 Topical calcineurin inhibitors have been tried in the treatment of AA. The 
peculiarity of tacrolimus was that the induction of anagen . However, there has 
not been a positive result with tacrolimus 0.1% applied twice daily even after 24 
weeks in patients with AA. 
 
Topical retinoids 
 Among topical retinoids, tretinoin and bexarotene have been tried in 
alopecia areata with mixed results. Irritation of the skin is a very common side 
effect and the efficacy is doubtful in the absence of double-blind randomized 
trials. 
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Prostaglandin analogs67: 
 The adverse effect of certain prostaglandin analogues used as anti-
glaucoma eye drops to cause hypertrichosis has been employed in treatment of 
alopecia areata. These prostaglandin analogues include Latanoprost and 
Bimatoprost and they are used in the treatment of alopecia areata involving the 
eyelashes. However, the results  have not been really encouraging. 
 
SYSTEMIC THERAPY: 
SYTSEMIC STEROIDS1,2,3,68: 
 Systemic steroids will  restore normal hair growth in many cases of AA. 
Systemic steroids have probably a place in controlling the spread of rapidly 
progressing Alopecia areta. They are frequently effective but their use is limited 
because of their adverse effects and high relapse rate after reduction of the dose. 
Systemic steroids have been used in the following regimens. 
 
A) One treatment regimen is to use 40 to 60 mg of prednisolone and to taper 
by 5mg every week. 
B) Oralmini pulse therapy with  betamthasone 5mg on two consecutive days 
for 3-6months 
C) Dexamethasone has been used as oral pulse on two consecutive days every 
week. The dose being 5mg in patient patient above 12 years and 2.5 to 3.5 
mg in children less than 12 years. 
D) Pulse therapy with intravenous methyl prednisolone (500mg) for 3 
successive days have also been used. 
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PUVA63 
 Oral PUVA has been used in the treatment of alopecia areata. In one study 
PUVA was administered to the whole body 3 times a week in patients suffering 
from extensive AA. This study concluded that PUVA could be used as an 
alternative therapy with extensive AA. However the long term utility of PUVA 
therapy is in doubt, as only 10% patient had cosmetically acceptable regrowth. 
 
SULFASALAZINE69 
 Sulfasalazine via the inhibition of inflammatory cells chemotaxis and 
cytokine antibody production to produce satisfactory results. Recommended dose 
is 0.5g twice daily for first month, then 1g twice daily for second month, 1.5 g for 
another three months. Complete regrowth was found in 27.3% and partial 
regrowth was foundin 40.9%. 
 
CYCLOSPORINE70 
 Cyclosporine is an immunosuppressant drug isolated from Norwegian 
fungus Tolypocladium inflatum. It inhibits helper t cells activation and suppresses 
interferon gamma production. it also prolongs the anagen phase of hair growth 
causing hypertrichosis as a cutaneous side effect.It is used either alone or in 
combination with systemic steroids. 
 
MISCELLANEOUS 
 Methotrexate71 had shown hair growth in 57% AA patients and when 
combined with prednisone, the efficacy was 63-64%  
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 Azathioprine72 was tried in an open label study by Farshi et al. at a dose of 
2 mg/kg/day for 6 months and reported 52.3% mean regrowth, using SALT score. 
Supplementation of anti-histamines like fexofenadine and ebastine have been 
found useful in AA, associated with atopic dermatitis. 
  
 Biologics73 like infliximab, etanercept, adalimumab and efalizumab have 
been tried, and all o them were unsuccessful. Some showed worsening or 
occurring of AA while on treatment with biologics. Abatacept has been found 
effective to prevent AA by blocking T-cell activation in experimental mouse 
models and was proposed for further clinical tests in AA. Capsaicin was tried in a 
recent randomized non-blinded study in 50 patients with patchy AA in 
comparison with 0.05% clobetasol ointment for 6 weeks, and 9.5%showed 
cosmetically acceptable regrowth at week 12 in both groups. 
 
 A combination of topical 5% garlic gel and betamethasone 1% cream for 3 
months showed statistically significant hair growth in more number of patients 
when compared to betamethasone and placebo. 
 
 Tincture iodine has been suggested as a non-specific irritant in patchy AA 
patients with less than 10 years of age. Topical bexarotene 1% gel was evaluated 
in single-blinded half head study and found 50% or more partial regrowth in 12% 
of patients on the treated side and in 14% responded on both sides. 
 
 Fractional Er: Glass laser has shown complete hair regrowth in a single 
patient who was not responding to conventional therapies.  
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 Topical tretinoin 0.05%, topical azelaic acid, inosiplex, topical onion juice, 
and intralesional candida antigen injections have been tried with some efficacy 
and need to be confirmed in large-scale, double-blind, placebo-controlled trials. 
 
 New drugs are being tried based on the GWAS against T-cell mechanisms 
and NK-cell activating ligands. Many drugs like anti-CD25, anti-CTLA-4, anti-
IL-6, anti-IL-15, and Syk inhibitor, which are being evaluated in other 
autoimmune diseases which affect these mechanisms,can be the potential 
therapies for clinical trials in AA. 
 
CAMOUFLAGE74 
 At times, when there  was no regrowth after various treatments, 
Camouflage techniques like hairpieces and hair additions may be tried. Hairpieces 
could be in the form of wigs, toupees, cascades  and wiglets. Human hair wigs are 
most expensive, needs regular shampooing  and lasts only 2-3 years. Synthetic 
hair fibers are less expensive, needs less maintenance and lasts for3-5 years.  
 
Future Therapeutic Options 
 Recombinant human bone morphogenetic protein is involved in hair 
morphogenesis. A patient of alopecia universalis who has put on this medication 
to hasten bone fracture healing showed dramatic hair growth all over the body. 
JAK (Janus kinase) inhibitors – oral Tofacitinib (JAK 1and 3 inhibitor) and 
ruxolitib (JAK 1 and 2 inhibitor) are the promising emerging drugs. 
 
Aims & Objectives 
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AIM OF THE STUDY 
 
 To study the efficacy of various modalities of treatment used in alopecia 
areata and to compare them with one another 
 The various modalities of treatment used in our present study are 
o Intralesional steroid with triamcinalone acetonide (10mg/ml) 
o Cryotherapy with liquid nitrogen 
o Topical phenol (88%) 
o Spot phototherapy with NBUVB 
  
 Materials and Methods 
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MATERIALS AND METHODS 
 
Study Design: 
 Prospective observation study 
 
Study approval : 
 Prior to commencement of this study - Thesis & Ethical Committee of 
Madras Medical College and Rajiv Gandhi Government General Hospital, 
Chennai had approved the thesis protocol. 
 
Place of study :  
 Department of Dermatology, Madras Medical College & 
 Rajiv Gandhi Govt. General Hospital ,Chennai – 600003 
 
Period of study : 
 Duration starting from  August 2017 to July 2018. 
 
 Patients presenting with alopecia areata to dermatology department of our 
hospital during the study period from August 2017 to July 2018 were recruited in 
the study. A diagnosis of Alopecia areata (AA) was made on clinical grounds, 
based on the following criteria. 
 
 Asymptomatic, circumcised, smooth, non scaly, non scarring patch of hair 
loss on the scalp. In doubtful cases a mycology opinion as obtained and fungal 
scraping from the patch was done to rule out tinea capitis. The age and sex of the 
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patients recruited were noted. A thorough history was elicited with regards to 
duration of symptoms, progression of disease, history of past episodes, history of 
any treatment , personal and family history of atopy, diabetes mellitus and 
hypertension and history suggestive of any other autoimmune diseases were also 
elicited.  
 
 A meticulous general and systemic examination was performed. Complete 
dermatological examination was performed taking care to note any other 
dermatoses in the patient. Nail changes and mucosal changes were noted. 
 
 The location of the patches of  AA, with reference to the size, presence of 
hair in the patches was also made. The presence of exclamation mark hair , 
coudability sign and pluckablity of hair at the margins was also  recorded. 
 
 A dental and ENT  opinion was sought to rule out septic foci. A complete 
haemogram was carried out in all patients and a random blood sugar in adults was 
done. The individuals with the history of exposure to the risk of sexually 
transmitted disease were subjected to a blood VDRL examination. 
 
 After completing the examination 100 patients were taken in the 
therapeutic study based on the following criteria.  
 
INCLUSION CRITERIA : 
 Patients having only scalp involvement.  
 Patients who had no treatment either topical or systemic in the past 3 
months.  
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 Before starting the therapy appropriate treatment of focal sepsis if any were 
given to the patient.  
 
EXCLUSION CRITERIA : 
 Patient not willing for study 
 Patient with alopecia universalis , totalis 
 Patients with oophiasis  and sisaipho pattern 
 Patients with  other systemic illness – cardiac , renal ,hepatic illness, 
severely Immunocompromised 
 
Pregnancy 
 Patients who have cold intolerance 
 Patients taking photosensitive drugs 
 Patients with history of photosensitivity 
 
 A total number of 100 patients were included in the study. A written 
informed consent was taken from each patient before starting the study.The 
patients were divided into 4 groups randomly , comprising 25 in each group and 
the following therapy was initiated.. 
 
GROUP I : PATIENTS TREATED WITH INTRALESIONAL STEROID 
 Corticosteroids, because of their anti-inflammatory activity, have been the 
mainstay of therapy for AA. They have been used topically, orally, and 
parenterally. Intralesional corticosteroids have been used since 1958 in the 
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treatment of AA, and it is the treatment of choice for adults in patchy AA, with 
approximate success rates of 60-75% 
 
 Twenty five patients comprising the first group were treated with 
intralesional steroid  (triamcinalone acetonide ). Injection triamcinalone acetonide  
at concentration of 10mg/ml was given deep into the dermis using a 0.5-inch long 
30-gauge needle at multiple sites, 1 cm apart and 0.1 ml into each site. The 
maximum dose should not exceed 20 mg for each visit. The treatment is repeated 
once in 4 weeks.  The patients were followed up once in 2weeks till the end of 
study period. 
 
GROUP II : PATIENTS TREATED WITH CYOTHERAPY 
 The second group of twenty five patients was given cryotherapy with 
liquid nitrogen. It was applied over the patches of AA with a cotton wool liquid 
applicator producing 2 – 3 freeze thaw cycles at an interval of 2 – 3 seconds until 
an erythema developed over the patches. The treatment was repeated once in two 
weeks. 
 
GROUP III : PATIENTS TREATED WITH LIQUID PHENOL  
 Full strength liquefied phenol was prepared by keeping the bottle 
containing phenol crystals in hot water until dissolution of crystals. It was further 
diluted with water to make 88% phenol solution (88 ml liquefied pure phenol in 
100 ml water). 
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 The patch was degreased by scrubbing with savlon , followed by spirit and 
acetone. In a small glass container, 0.5-1 ml 88% phenol was taken which was 
then applied gently with thin cotton tipped applicator until an ivory white uniform 
frosting was seen. Neutralization is not required.  Treatment was repeated at 3 
weekly intervals. 
 
GROUP IV : PATIENTS ON PHOTOTHERAPY  
 For the last group of twenty five patients phototherapy was given with 
hand held NB-UVB device directly over the AA patch. Patch was exposed to 
NBUVB with initial dose of 200 mJ/cm 2,  thrice weekly  with increments of 10% 
at every week, till minimal erythema developed.. After that, follow-ups were done 
fortnightly completing a total period of 12 weeks.  
 
 The patients were reviewed once in 15days. All the selected patches were 
assessed clinically as well as photographically at the baseline, at each visit, and at 
each follow-up visit. The following changes were noted and recorded. 
 
 Increase in size of the lesions. 
 Appearance of new lesions 
 
Response to therapy was noted as follows 
 No regrowth of hair 
 Appearance of vellus hair 
 Growth of pigmented normal hair 
 Extent of regrowth 
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Complication of therapy like 
 Burning and irritation 
 Erythema 
 Vesiculation 
 Pigmentary changes 
 Folliculitis 
 Atrophy 
 
Patient's response to the treatment was graded as follows : 
0-25% A Hair regrowth covering < 25% of the patch. Very poor response 
25-50% B 
Hair regrowth occurs, but is not cosmetically acceptable to 
the patients. 
Poor response 
50-75% C 
Hair regrowth is cosmetically acceptable and cover ¾ of the 
patch. 
Moderate response 
75-90% D 
Hair regrowth covered almost all of the patch, but the hair 
was not of similar density to the surrounding hair. 
Good response 
90-100% E 
Complete regrowth of hair, which is indistinguishable from 
the surrounding area. 
Excellent response 
 
 Results were analyzed photographically as well as statistically (using  
Chi-square test) after a follow-up period of 12 weeks. 
 
 For the purpose of statistical analysis, comparison & interpretation patients 
with excellent, good & moderate response were considered to have cosmetically 
acceptable regrowth and those patients with very poor and poor response were 
considered to have unacceptable regrowth. 
Observations & Results 
  
43 
 
 
 
OBSERVATIONS 
 
An analysis of the clinical profile of the patients recruited for the therapeutic 
response revealed the following data. 
 
 There were 43(43%) females & 57(57%) males in the study groups. 
 
 The age of the patient ranged from 7 to 49 years and the mean age is 
27.48years (SD - 7.87years). 
 
  
 
 The duration of the disease ranged from two weeks to 2 years, average 
duration being 5.65 months (SD - 4.75). 
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Variables Intralesional steroid Cryotherapy 
Topical 
phenol 
Spot 
phototherapy 
Duration 
(months) 
Mean 4.90 6.34 7.34 4.02 
SD 3.77 5.11 5.76 3.58 
 
 11 patients had a family history of atopy. There was a personal history of 
atopy in 19 patients in the form of chronic urticaria (8), allergic rhinitis (6), 
bronchial asthma (3), pityriasis alba (1) atopic dermatitis in one patient. 
 
Variables Frequency N (%) 
Atopy 
Present 19 (19%) 
Absent 81 (81%) 
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45 
 
 Nine patients had association of other autoimmune disorders which 
includes multinodular goitre in three patients, vitiligo in three patients, 
hypothyroidism in two patients and lichen planus in one patient. One patient with 
multinodular goitre was in addition on antipsychotic medication 
 
 10 patients had past history of alopecia areata . In addition to the family 
history of atopy recorded earlier, 22 & 15 patients had family history of DM and 
hypertension respectively. 
 
Examination of the patches of AA revealed the following: 
 The number of patches varied from 1 to 8, the average being 2 (SD-1). The 
size of the smallest patch was 1x1cm and the size of the largest patch was 5 X 4 
cm. The coudability sign and exclamation mark hair were positive in 69 and 81 
patients respectively. 
 
 Out of 100 patients, 43 patients (43%) had single patch and remaining 57 
patients (57%) had multiple patches. 
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 The region wise distributions of the patches were occipital (63), parietal 
(57), frontal (4) and temporal (22).  
 
 
 The nail changes were noticed in 34 patients which includes – pitting in 18 
patients, leuconychia in 7, longitudinal ridges in 6, bues line in 1, melanonychia in 
1, onycholysis in 1 patient. One patient had pitting associated with leuconychia, 
48% 52%
40%
32%
52% 48%
60%
68%
0%
10%
20%
30%
40%
50%
60%
70%
80%
Intralesional
steroid
Cryotherapy Topical phenol Spot photherapy
Pe
rc
en
ta
ge
Different treatment methods
Patches Vs Each treatment group
Single Multiple
63%
57%
22%
4%
0%
10%
20%
30%
40%
50%
60%
70%
Occipital Parietal Temporal Frontal
Pe
rc
en
ta
ge
Different sites
Patch site
47 
 
1patient had pitting and onycholysis and 2 patients had pitting and trachyonychia. 
Two patients had hyper pigmentation of oral mucosa. 
 
Variables Frequency N (%) 
Nails changes 
Present 34 (34%) 
Absent 66 (66%) 
 
 
 
 Other associated dermatological manifestations were dermatophytosis (2), 
psoriasis, verruca vulgaris, lichen simplex chronicus, intertrigo  and seborrheic 
dermatitis each in 1 patient. Clinical examination of focal sepsis revealed chronic 
gingivitis in 1 patient, dental caries in 5 and pharyngitis in 1 patient. 
Eight patients were found to be diabetic and 3 patients had systemic hypertension, 
all patients were on regular treatment. 
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OBSERVATION OF THERAPEUTIC RESPONSES 
 In our study group of 100 patients, there was no significant difference in 
the mean age and gender distribution among different study groups. 
 
 Acceptable regrowth (excellent, good and moderate) was found in 63 
patients (63%) and remaining 37 patients (37%) had cosmetically unacceptable 
regrowth (poor and very poor response)  
 
 
 
S 
No Variables 
Intralesional 
steroid 
Cryo 
therapy 
Topical 
phenol 
Spot 
phototherapy 
N (%) 
1 Response 
Acceptable 22 (88%) 19 (76%) 
13 
(52%) 9 (36%) 
Unacceptable 3 (12%) 6 (24%) 12 (48%) 16 64%) 
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 Cosmetically acceptable regrowth of hair was seen in 88% of patients 
treated with intralesional steroids, 76% of patients with cryotherapy, 52 % in 
patients treated with phenol and 36%of patients treated with phototherapy with 
NBUVB. 
 
 
 
 Excellent response occurred in 48% (12patients) treated with ILS, 28% 
(7patients) with cryotherapy,16% (4patients ) with phenol , 8% (2 patients) with 
NBUVB. 
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Atopic patients  responded poor to the treatment comparing to non atopics and 
this difference is statistically significant. 
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Variables 
Response 
Acceptable Unacceptable 
Atopy 
Present 6 (31.6%) 13 (68.4%) 
Absent 57 (70.4%) 24 (29.6%) 
Chi- square value – 9.93 
p value 0.002 (statistically significant) 
 
 
 
 There is statistically significant difference in treatment response in patient 
with associated nail changes and in patients without nail changes.  
 
Variables Response 
Acceptable Unacceptable 
Nails changes Present 14 (41.2%) 20 (58.8%) 
Absent 49 (74.2%) 17 (25.8%) 
Chi- square value – 10.52 
p value  0.001 (statistically significant) 
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 The number of patches (single/ multiple)  among different study groups 
doesn’t influence the response outcome 
 
Treatment type Variable 
Response 
Acceptable Unacceptable 
Cryotherapy Patch cat 
Single 12 (92.3%) 1 (7.7%) 
Multiple 7 (58.3%) 5 (41.7%) 
Chisquare (Fischer exact)-  3.94 
p value – 0.07 (not statistically significant) 
 
Treatment type Variable 
Response 
Acceptable Unacceptable 
Intralesional 
steroid Patch cat 
Single 12 (100%) 0 
Multiple 10 (76.9%) 3 (23.1%) 
Chisquare (Fischer exact)-  3.14 
p value – 0.22 (not statistically significant) 
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Treatment type Variable 
Response 
Acceptable Unacceptable 
Spot phototherapy Patch cat 
Single 4 (50%) 4 (50%) 
Multiple 5 (29.4%) 12 (70.6%) 
Chisquare (Fischer exact)-  1.001 
p value –0.394  (not statistically significant) 
 
 
Treatment type Variable 
Response 
Acceptable Unacceptable 
Topical phenol Patch cat 
Single 7 (70%) 3 (30%) 
Multiple 6 (40%) 9 (60%) 
Chisquare (Fischer exact)-  2.16 
p value – 0.226 (not statistically significant) 
 
 Patients with past history of alopecia areata responded poor than patients 
with new onset of alopecia areata. 
 
Variables 
Response 
Acceptable Unacceptable 
Pasth/oAA 
Present 3(30%) 7(70%) 
Absent 60(66.7%) 30(33.3%) 
Chi-square value(Fischer Exact)–5.19 
pvalue0.022(statistically significant) 
 
 
54 
 
 
 
 
GROUP I: RESULTS OBTAINED WITH INTRALESIONAL STEROIDS. 
 The mean age of the patients included in this group was 28.36 years and 
the mean duration was 4.90. 
 
 Numbers of patches range from 1 to 3 ,with 12 patients (48%) had single 
patch and 8 patients (32%) had two patches and remaining5 patients (20%)had 3 
patches. The size of patch ranges from 1x1 to 5x3 cm. 
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 Associated nail changes were found in 7 patients (28%). Atopy was found 
to be associated with 5 patients (20%). 12 patients (48%) had singe patch and 
multiple patches were found in 13 patients (52%).Past history of AA was found in 
3 patients (12%). 4patients (16%) were found to be diabetic and 2 patients (8%) 
were found to have systemic hypertension. 
 
 Among the 25 patients treated with intra lesional steroids, acceptable 
regrowth of hair occurred in 22 patients (88%) of which 12(48%) patients showed 
excellent response and 7(28%) patients showed good response & 3(12%) patients 
showed moderate response. Poor response was seen in 2(8%) patients and very 
poor response in one patient(4%). 
 
  
  
 Regrowth of hair started after 4 weeks in seven, after 6 weeks in five 
patients with excellent response. In patients with poor response regrowth of hair 
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started only after 8 weeks but the density of hair regrowth continued to be poor 
during the study period. Patients with very poor response showed no growth at all 
except for vellus growth of hair which was poor during the entire study period. 
 
 One patient with good response and one patient with moderate response 
developed new patch during the treatment period. 
 
 One patient developed atrophy at the treatment site which was transient and 
resolved spontaneously. Two patients developed mild pain at the injection site. 
 
 The initial regrowth of hair was in the form of depigmented hair in 9 
patients which showed very slow repigmentation.  
 
 Patients who had past history of alopecia areata responded poor to 
treatment compared to those without past history and this difference is statistically 
significant (p =0.02).  
 
Treatment type Variable 
Response 
Acceptable Unacceptable 
Intralesional 
steroid Past h/o 
Present 1 (3.3%) 2 (66.7%) 
Absent 21 (95.5%) 1 (4.5%) 
Chisquare (Fischer exact)-  9.64 
p value – 0.02 (statistically significant) 
 
 There is significant difference in treatment response in those patients with 
associated nail changes (p=0.015). Patients without associated nail changes 
responded well to intralesional steroids.  
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Treatment type Variable 
Response 
Acceptable Unacceptable 
Intralesional steroid Nail changes 
Present 4 (57.1%) 3 (42.9%) 
Absent 18 (100%) 0 (0%) 
Chi square (Fischer exact)-  8.76 
p value – 0.015  (statistically significant) 
 
 History of atopy doesn’t influence the treatment response in this study 
group (p=0.09). 
 
 
GROUP II: RESULTS OBTAINED WITH CRYOTHERAPY 
 The mean age of the patients included in this group was 25.92 years and 
mean duration was 6.34 months. 
 
 Numbers of patches range from 1 to 4, with 13 patients (52%) had single 
patch and 7 patients (28%) had two patches, 4 patients (16%) had 3 patches and 
remaining one patient (4%) had patches.  
 
 The size of patch ranges from 1x1 to 5x4 cm. Associated nail changes were 
found in 9 patients (36%). Atopy was found to be associated with 7 patients 
(28%). 13 patients (52%) had singe patch and multiple patches were found in 12 
patients (48%).Past history of AA was found in 4 patients (16%). 1patients (4%) 
was found to be diabetic. 
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 Acceptable regrowth of hair occurred in 19 (76%) patients of which 
7(28%) patients had excellent response and 7(28%) patients showed good 
response & 5(20%) patients showed moderate response. Poor response was seen 
in 3(12%) patients and very poor response in 3 (12%) patients. 
 
 
  
 In patients with excellent response, regrowth of hair started by 4 weeks in 
four patients and by 6 weeks in three patients.  In patients with good response, 
regrowth started by four weeks in 4 patients and by six weeks in three patients. In 
patients with poor response, regrowth started by 8th week in two patients and by 
10th week in one patient. 
 
 One patient with excellent response showed initial increase in extension of 
patch at the margins but it was improved with subsequent treatment. 
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 The untoward effects noticed by the patients at the time of treatment were 
erythema in two patients and edema in two patients which was bearable. 
 
 In this group, the association of atopy with treatment response is 
statistically significant (p=0.032). Patients without  history of atopy responded 
well.  
 
Treatment type Variable 
Response 
Acceptable Unacceptable 
Cryotherapy Atopy 
Present 3 (42.9%) 4 (57.1%) 
Absent 16 (88.9%) 2 (11.1%) 
Chisquare (Fischer exact)- 5.85 
p value – 0.032 (statistically significant) 
 
 The severity of nail changes influenced the treatment response which is 
statistically significant (p=0.012).  
 
Treatment type Variable 
Response 
Acceptable Unacceptable 
Cryotherapy Nail changes 
Present 4 (44.4%) 5 (55.6%) 
Absent 15 (93.8%) 1 (6.3%) 
Chisquare (Fischer exact)-  7.67 
p value – 0.012 (statistically significant) 
 
There is no significant association of treatment response with number of patches. 
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GROUP III: RESULTS OBTAINED WITH TOPICAL PHENOL 
 The mean age of the patients in this group was 29.88 years and the mean 
duration was 7.34 months. 
 
 Numbers of patches range from 1 to 3 , with 10 patients (40%) had single 
patch and 10 patients (40%) had two patches,  4 patients (16%) had 3 patches and 
remaining one patient (4%)  had 4 patches. The size of patch ranges from 1x1 to 
4x4 cm. Associated nail changes were found in 9 patients (36%). Atopy was 
found to be associated with 4 patients (16%). 10 patients (40%) had singe patch 
and multiple patches were found in 15 patients (60%).Past history of AA was 
found in 3 patients (12%). 2 patients (8%) were found to be diabetic. 
 
 Among the 25 patients treated with phenol, acceptable hair regrowth was 
found in 13(52%) patients, of which four(16%) had excellent response, six(24%) 
had good response and three patients(12%) had moderate response. Poor response 
was noticed in seven patients(28%) and five patients(20%) showed very poor 
response.  
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 In patients with excellent response, hair regrowth was started by 4weeks in 
two patients and 6weeks in two patients. Complete hair regrowth was noted only 
by end of 12th week. In one of the patients there was increase in size of the patch 
during therapy but hair regrowth was complete. 
 
 In patients with good response, the patients started regrowing hair between 
4 and 8 weeks.  
 
 In patients with moderate response, regrowth was started by 6 weeks and 
completed by 10weeks. The patch continued to increase in size at the margins. 
 
 The patients with very poor response did not show any evidence of hair 
regrowth. 
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 Six out of twenty five patients developed adverse effects following 
treatment. Among them three patients showed hypo pigmentation. Hyper 
pigmentation, erythema, mild atrophy was seen each in one patient. 
 
 Patients with history of atopy responded poor to treatment and this 
difference is statistically significant (p=0.039).  
 
Treatment type Variable 
Response 
Acceptable Unacceptable 
Topical phenol Atopy 
Present 0 (0%) 4 (100%) 
Absent 13 (61.9%) 8 (38.1%) 
Chisquare (Fischer exact)-  5.15 
p value – 0.039  (statistically significant) 
 
GROUP IV: RESULTS OBTAINED WITH PHOTOTHERAPY 
 Acceptable hair regrowth was noted in 9(36%) out of 25 patients. Numbers 
of patches range from 1 to 8 , with 8 patients (32%) had single patch and 13 
patients (52%) had two patches, 1 patient(4%) had three patch, 2 patients(8%) had 
4 patches and remaining 1 patients (4%)had 8 patches.  
 
 The size of patch ranges from 1x1 to 5x4 cm. Associated nail changes were 
found in 9 patients (36%). Atopy was found to be associated with 3 patients 
(12%). 8 patients (32%) had single patch and multiple patches were found in 17 
patients (68%). 1patient (4%) were found to be diabetic and 1 patient (4%) were 
found to have systemic hypertension. 
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  Among them excellent response was seen in two patients(8%), good 
response in four(16%) and moderate response in three patients(12%). 11 patients 
showed poor response(44%) and 5 patients showed very poor response(20%). 
 
 
 
 
 In patients showing excellent response, the hair regrowth started at 4weeks 
with gradual increase in thickness and density of hair. In patients with good 
response, regrowth started by 4weeks in two patients and 6 weeks in two patients. 
In patients with poor response, regrowth started by 6 to 8weeks but there was no 
improvement in density.   
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 In patients with very poor response there was no regrowth of hair. None of 
the patients in this study group developed new patch during the study period. 
Adverse effects in the form of erythema and burning sensation developed in three 
patients during the first week of therapy. These effects were mild and tolerable 
and the patients wished to continue the therapy. 
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DISCUSSION 
 
 In this study of 100 patients with age ranging from 7 to 49 years, the 
maximum number of 74 patients was in the age group of 21-40 years , 22 patients 
were in age group of less than 20 years and the minimum number of four subjects 
was in 40-49 years age group. 
 
 
 
 Thus, a total of 90% occurred below the age of 40 years, which shows 
decreasing incidence with age. This observation was similar to another study 
which states that 85.5% of the Asian patients with AA have disease onset before 
40 years of age85.  
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 Males outnumbered the females in this study; there were 57% males and 
43% females. Some studies show a significant male preponderance in the adult 
age group, although others identify contrasting results86. 
 
 
 
 Nail changes were evident in 34% of the total 100 patients in the form of 
leukonychia, pitting, longitudinal ridging, onycholysis and beau's lines. 
 
 Gandhi et al. observed pitting to be the most common nail finding in 
patients with alopecia areata, which is similar to our study87. 
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GROUP I: PATIENTS TREATED WITH INTRALESIONAL STEROIDS 
 
 In this group of 25 patients, there were 15 male (60%) and 10 female 
(40%). The duration of the disease ranges from 2weeks to twelve months (mean – 
4.90).  
 
 Acceptable regrowth of hair occurred in 88% (22patients), of which 12 
patients showed excellent response and 7 patients showed good response & 3 
patients showed moderate response. Poor response was seen in 2 patients and very 
poor response in one patient.  
 
 Amirnia et al78 found the efficacy of ILS was 83.3%, which is comparable 
to our study and he has also found a statistically significant response in patients 
treated with ILS compared to cryotherapy (P= 0.05). 
 
 Chang, Kyung Hee75 et al showed in his study that six out of ten patients 
showed considerable improvement in contrast to our study where 88% 
improvement occurred. Abell and Munro55 in 1973 reported hair regrowth in 62% 
of the patients at 4-6 weeks with Triamcinolone acetonide (using the Porto-jet 
injector) compared with 7% in control subjects injected with isotonic saline. 
Another  study by Mona et al, showed that intralesional steroid has better hair 
regrowth 74.3% as compared to topical betamethasone which showed efficacy of 
46.9%84 
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 100% of cases with single patch improved and 76.9% improvement 
occurred in patients with multiple patches, unlike in other studies where extensive 
AA is of little improvement76 which shows number of patches having no influence 
in the response outcome. 
 
 One patient each with poor and very poor response and 2 patients with 
good response had personal history of atopy. Two patients with good and 
excellent response  and one patient with poor response also had family history of 
atopy, so atopy doesn’t alter the course of the disease 
 
 Two patients with excellent response had dental sepsis and one patient with 
good response had chronic gingivitis, which was treated. 
 
 One patient with good and moderate response developed new patches 
elsewhere. This showed that though treatment was initiated it did not alter the 
course of the disease progression. 
 
 Intralesional Triamcinolone acetonide is a safe and effective treatment for 
patients with extensive alopecia areata. 
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GROUP II: PATIENTS TREATED WITH CRYOTHERAPY 
 In patients treated with cryotherapy, there were 12 male (48%) and 13 
female (52%). The duration of the disease ranges from 2weeks to eighteen months 
(mean – 6.34).  
 
 76% (19 out of 25) patients showed acceptable regrowth of hair. Kim et 
al. reported that superficial cryotherapy showed therapeutic efficacy in 24 of 36 
AA patients (66.7%)79. 
 
 Out of 19, 7 patients had excellent response and 7 patients showed good 
response & 5 patients showed moderate response. 
 
 Zawar et al77 studied the efficacy of cryotherapy in recalcitrant 
alopeciaareata and reported sustained hair regrowth in 80% patients. 
 
 Lei et al in his study65  showed that hair regrowth occurred in greater than 
60% of affected areas in 70 of 72 patients, which is in contrast to our study 
wherein 76% of the patients showed improvement. 
 
 Regrowth of  hair was first noticed between two to four weeks in eight 
patients which is comparable to earlier studies where regrowth was reported by 
two weeks65 
  
70 
 
 
 One patient with excellent response had dental caries and one patient with 
good response had chronic pharyngitis. Hence in this group focal sepsis doesn’t 
seem to influence the response outcome. 
 
 80.0% of the patients with single and multiple patches showed 
improvement which shows that there is no significance in the number of patches 
in the response outcome. 
 
 From the above it can be concluded that liquid nitrogen seems to be one of 
the  cost effective therapy that could be tried in the treatment of alopecia areata. 
 
GROUP III: RESULTS OBTAINED WITH TOPICAL PHENOL 
 There were14 male (56%) and 11 female (44%). The duration of the 
disease ranges from 2weeks to two years (mean – 7.34).  
 
 The mean age of the patients in this group was 29.88 years and the mean 
duration was 7.34 months. 
 
 Among the 25 patients treated with phenol, acceptable hair regrowth was 
found in 13(52%) patients, of which four had excellent response, six had good 
response and three patients had moderate response. 
 
 A study done by Mehta et al80 found 47.06% response at the end of three 
months in patients treated with phenol, which  is comparable to our study which 
showed 52% response rate. Another study by Ravi et al83 showed 66.7% response 
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for 88% phenol. Ravi et al also found intralesional corticosteroids were found to 
be more effective than topical phenol, which is similar to our study. Savant et al in 
his study showed 72.5% good response and 27.5% poor response. 
 
 Poor response was noticed in seven patients and five patients showed very 
poor response.  
 
 88% phenol can be considered as a treatment option for stable alopecia 
areata due to its low cost, ease of application and  easy availability. 
 
GROUP IV: RESULTS OBTAINED WITH PHOTOTHERAPY 
 In this group of 25 patients, there were 16 males (64%) and 9 females 
(36%). The duration of the disease ranges from 2weeks to fifteen months (mean – 
4.02).   
 
 Acceptable hair regrowth was noted in 9(36%) out of 25 patients.  Among 
them excellent response was seen in two patients, good response in four and 
moderate response in three patients.  11 patients showed poor response and 5 
patients showed very poor response. 
 
 Bayramgürler et al82. which showed an excellent response in 20% of 
patients. 
 
 Kaur et al83  in his study showed 17.5% patients  had more than 50%of hair  
regrowth which is lower than our study. 
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 Larger sample size and long term follow up are needed to assess the long 
term outcome of this treatment modality.  
 
 Among the different modalities of treatment used in our study, intralesional 
steroids were found to be superior than other treatment modalities. Statistically 
significant difference in treatment response was found between patients treated 
with intralesional steroid and topical phenol(p=0.005), intralesional steroids and 
phototherapy (p=0.001) , cryotherapy and phototherapy ( p= 0.004). 
 
Variable 
Response 
Acceptable Unacceptable 
Treatment 
Intralesional 
steroid 22(88%) 3(12%) 
Topical phenol 13(52%) 12(48%) 
Chisquare–7.71 
pvalue–0.005 (statistically significant) 
 
 
Variable 
Response 
Acceptable Unacceptable 
Treatment 
Intralesional steroid 22(88%) 3(12%) 
Spot phototherapy 9(36%) 16(64%) 
Chisquare–14.34 
pvalue–0.0001(statistically significant) 
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Variable 
Response 
Acceptable Unacceptable 
Treatment 
Cryotherapy 19(76%) 6(24%) 
Spot phototherapy 9(36%) 16(64%) 
Chisquare–8.11 
pvalue–0.004(statistically significant) 
 
  
Conclusion 
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CONCLUSION 
 
1. Cosmetically acceptable regrowth of hair was seen in 88% of patients 
treated with intralesional steroids, 76% of patients with cryotherapy, 52 % 
in patients treated with phenol and 36%of patients treated with 
phototherapy with NBUVB. 
2. Excellent response occurred in 48%(12patients ) treated with ILS, 28% 
(7patients) with cryotherapy,16%(4patients ) with phenol , 8%(2 patients) 
with NBUVB 
3. Statistically significant improvement occurred in patients treated with 
intralesional steroids and topical phenol (p=0.005), intralesional steroids 
and phototherapy (p=0.001) , cryotherapy and phototherapy ( p= 0.004). 
4. Atopy in the form of personal and family history was the only significant 
association found in the present study group (30% patients) 
5. Nail changes were seen in 34% of patients, with pitting as the most 
common finding. 
6.  Prevalence of alopecia areata is slightly higher in males compared to 
females. Higher incidence was found between 21 – 40 years of age 
7. Statistically significant association was found between the association of 
atopy and treatment response (p= 0.002) 
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8. Statistically significant association was found  between the association of  
nail changes and treatment response (p= 0.001) 
9. The number of patches (single/ multiple)  among different study groups 
doesn’t influence the response outcome (P=0.26). 
10. All the four treatment modalities produced only transient adverse effects 
which did not      interfere with the patient compliance.  
11. All the four modalities listed above may be considered in the therapy of 
alopecia areata as the adverse effect noticed were transient. Role of 
NBUVB in treatment of alopecia areata needs further evaluation in large 
group of patients 
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P    - PARIETAL 
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Ph               - PHARYNGITIS 
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HYPOTHY
ROID
 -  -  -  -  -  -  -  -
OTHERS  -  -  -  -  -  -  -  -  -
INTERTRIG
O
 -  -  -  -  -  -  -  -  -  -  -  - LSC  -  -
PAST HISTORY OF 
AA
 -  -  +  -  -  -  -  -  -  -  +  -  -  -  -  -  -  +  -  -  -  -  -  +  -
GEN. EXM N DC N N N N N N N N N PH N N N N N N N N N N N N N
SYS. EXM N N N N N N N N N N N N N N N N N N N N N N N N N
DERM EXM
NO OF PATCHES 1 1 2 1 1 1 2 2 3 1 3 1 1 1 2 1 1 3 2 1 2 1 3 4 2
SITE O P O,P O P O O,T P,T P(2),T O O,P,T P F P P,F P T O,T(3) O P T,P P O, P(2) O(2), P(2) O
SIZE( CM) 3X2 2X2 3X2,3X3 4X3 3X2 2X2 4X3,3X2 5X4.2X1 4X4- 1X1 3X2 3X2- 1X1 2X2 3X2 3X2 4X3,3X2 2X2 3X2 4X3-1X1 3X2,1X1 2X2 3X3,3X2 5X4 4X4-2X2 5X4-2X1 3X2-,2X2
NAILS L   - PITS  -  -  - L  - LG  - PITS  -  -  -  -  - PITS, T L  -  -  -  -  - PITS BL
RESPONSE AT 12 
WEEKS
C E B C E D D A B C D D E E C E A B D E E D C A D
MASTER CHART FOR PATIENTS ON CRYOTHERAPY
S/NO 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25
AGE 19 23 26 33 36 31 29 41 38 37 19 27 28 40 36 34 23 28 29 19 31 37 29 27 27
SEX M M F M F M F M M M F F M M M F F M F M F M M F F
DURATION(MONT
HS)
3 1 0.5 3 12 18 9 4 24 5 6 8 12 15 10 2 6 7 1 12 9 2 3 5 6
SYMPTOMS  -  -  -  -  -  - ITCH  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -
TREATMENT 
HISTORY
TOPICAL  -  -  -  -  -  +  -  -  +  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -
SYSTEMIC  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -
FAMILY HISTORY
DM  -  -  -  +  -  -  +  -  -  -  -  -  -  -  +  -  -  -  -  -  -  +  -  -  +
HT  -  -  -  -  -  -  -  -  +  +  -  -  -  -  +  -  -  -  -  -  -  +  -  -  -
ATOPY  -  +  -  -  +  -  -  -  -  -  -  -  -  -  -  -  -  -  +  -  -  -  -  -  -
PERSONAL 
HISTORY
DM  -  -  -  -  -  -  -  +  -  -  -  -  -  +  -  -  -  -  -  -  -  -  -  -  -
HT  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -
ATOPY AR  -  -  - CU  -  -  -  -  -  -  -  -  - CU  -  -  -  - AD  -  -  -  -  -
AUTOIMMUNE  -  -  -  -  -  -  -  - VV  -  -  -  -  -  -  - LP  -  -  -  -  -  -  -  -
OTHERS  N N N N N N N N N N VERRUCA N N N N N SEBDERM N N N N N N N N
PAST HISTORY OF 
AA
 -  -  -  +  -  -  -  -  -  +  -  -  -  -  -  -  -  -  -  -  +  -  -  -  -
GEN. EXM  N N N N N DC N N N N N N N N N N N N N N N N N N N
SYS. EXM N N N N N N N N N N N N N N N N N N N N N N N N N
DERM EXM
NO OF PATCHES 1 1 1 2 1 3 2 1 3 4 3 2 2 3 2 1 2 2 1 2 2 2 1 1 1
SITE O P P O,P P O(2), P P,T O O(2),T O(2), P(2) O, P(2) O,P O O,P(2) O P T O,T O P O O,P P O O
SIZE( CM) 4X3 3X3 4X2 3X2-2X1 3X2 4X3-2X1 3X2,2X2 3X2 4X3-2X1 4X3-2X2 4X3-1X1 3X2,2X2 4X3,3X2 4X3-2X1 3X3,2X1 3X2 3X2,2X1 3X2,2X1 3X2 4X3,3X2 4X4,3X2 3X3,2X2 3X2 3X2 3X3
NAILS  -  - OL, PITS  -  - PITS  -  - LG   -  -  -  - PITS  -  -  -  - PITS,T PITS PITS LG  -  - L
RESPONSE AT 12 
WEEKS
B C E D A B C D A A B D B A A D D C E B B D E E B
MASTER CHART FOR PATIENTS ON TOPICAL PHENOL
S/NO 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25
AGE 27 29 21 22 28 36 28 21 23 19 16 32 30 27 23 29 28 31 34 20 27 37 25 19 12
SEX M F M F M M M F M M F M M F F M M M F M M F M M F
DURATION(MONT
HS)
1 1 2 0.5 6 2 4 2.5 3 1 1 1.5 2 12 7 9 15 5 3 1 5 3 5 3 5
SYMPTOMS  -  -  -  -  -  -  -   -  -  -  -  -  - ITCHING  -  -  -  -  -  -  -  -  -  -  -
TREATMENT 
HISTORY
TOPICAL  +  -  -  -  -  -   +  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -
SYSTEMIC  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -
FAMILY HISTORY
DM  -  -  -  -  +  -  -  -  -  -  -  -  +  -  -  +  -  -  +  -  -  -  -  -  -
HT  -  -  -  -  -  +  -  -  -  -  -  +  +  -  -  -  -  -  -  -  -  +  -  -  +
ATOPY  -  +  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  +  -  -  -  -  -  -
PERSONAL 
HISTORY
DM  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  +  -  -  -
HT  -  -  -  -  -  +  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -   -
ATOPY  CU  -  -  -  -  -  -  -  -  -  - CU  -  -  -  -  -  -  - AR  -  -  -  -  -
AUTOIMMUNE v MNG  -  -  -  -  -  -  -  -  -  - VV  -  -  -  -  -  -  -  -  -  -  -  -
OTHERS  -  -
T.CORPOR
IS
 -  -  -  -  -  -  -  -  -  -  -  - PSORIASIS  -  -  -  -  -  -  -  -  -
PAST HISTORY OF 
AA
GEN. EXM N N N N N N N N DC N N N N N N N N N N N N N N N N
SYS. EXM N N N N N N N N N N N N N N N N N N N N N N N N N
DERM EXM
NO OF PATCHES 4 2 2 1 2 2 8 2 1 1 2 1 3 2 2 2 4 1 1 1 2 1 2 2 2
SITE O(2),P,F O,P O P O,P O,T
O(3), 
P(2),T(2),F
O P T O P O(2),P O O,P P,T O,P(2),T O P O P,T O T,P O,P O,P
SIZE( CM) 4X4 -2X2 3X2,2X2 4X3,3X2 3X3 X3,3X2 3X2,2X2 3X3-1X1 3X3,3X2 4X3 3X2 3X2,2X1 3X2 3X2-2X1 3X3,3X2 2X2,2X1 2X2,2X1 4X3-2X1 3X2 3X2 3X3 5X4-2X1 3X2 2X2,3X2 3X2,2X1 2X2,4X2
NAILS LG L OL PITS, L PITS LG PITS M PITS
RESPONSE AT 12 
WEEKS
B C B E B C A B D B B A B B C A B D A B B D A D E
MASTER CHART FOR PATIENTS ON  SPOT PHOTOTHERAPY
S/NO AGE SEX
NO OF 
PATCHES
DURATION 
(MONTHS)
ATOPY - 
FAMILY
ATOPY- 
PERSONAL
COUDABLI
TY SIGN
EXCLAMA
TION HAIR
2WKS  4 WKS 6WKS 8 WKS 10WKS 12WKS
ADVERSE 
EFFECTS
1 23 M 2 9  + AR  +  + A A A A A A  -
2 34 M 1 10  -  -  +  + A B B C D D  -
3 16 F 2 9  -  -  -  - A B C C D E  -
4 28 F 3 8  -  -  +  + A B B C C E  -
5 37 F 1 2  -  -  +  + A A B C D E  -
6 40 M 1 3  -  -  -  + A A B C C D  -
7 34 M 2 7  -  -  +  + A A B C D E  -
8 25 F 2 3  - CU  -  + A A A A B B  -
9 14 M 1 2  +  -  +  - A A B B C D  -
10 17 M 1 3  -  -  +  + A B C C D E
TRANSIENT 
ATROPHY
11 19 M 1 2  -  -  -  + A B C C D E  -
12 32 M 3 12  -  -  +  + A A B B C C  PAIN
13 29 F 2 1  - CU  -  + A A B C C D  -
14 41 M 3 3  -  -  +  + A A B B C C  -
15 31 F 1 1  -  -  -  - A B C C D E  -
16 36 F 1 0.5  +  -  +  + A B C D D E  -
17 24 M 1 1  -  -  +  + A A B C C E  -
18 21 F 2 1  - AR  +  + A A B C C D  -
19 31 F 1 2  -  -  -  + A A B C D E  -
20 19 M 3 7  -  -  +  + A B B C C D MINIMAL PAIN
21 20 M 3 12  -  -  -  - A A A A B B  -
22 23 M 2 9  -  -  -  - A A B C D E  -
23 27 M 2 8  -  -  +  + A A B C C D  -
24 39 F 1 5  - BA  -  - A A B B C C  -
25 49 M 1 2  -  -  +  + A B B C D E  -
TABLE 1- INTRALESIONAL STEROID
RESPONSE                                          PROFILE   OF   THE   PATIENTS
S/NO AGE SEX
NO OF 
PATCHES
DURATION(
MONTHS)
ATOPY- 
FAMILY
ATOPY -
PERSONAL
COUDABLI
TY SIGN
EXCLAMA
TION HAIR
2WKS 4WKS 6WKS 8WKS 10WKS 12WKS
ADVERSE 
REACTIONS
1 30 F 1 0.5  - AR  -  + A A B B C C  -
2 34 F 1 2  -  -  +  - A B C C D E  -
3 37 M 2 6  - BA  +  + A A A B B B EDEMA
4 26 F 1 3  +  -  +  + A A B B B C  -
5 23 M 1 2WEEKS  -  -  -  + A A B B C E  -
6 26 M 1 3  -  -  +  - A A B B C D  -
7 28 F 2 9  -  -  +  + A B B C C D  -
8 36 M 2 12  - BA  +  + A A A A A A  -
9 33 M 3 18  -  -  +  + A A A B B B ERYTHEMA
10 42 F 1 8  - CU  -  + A A B B C C  -
11 28 F 3 9  -  -  +  + A B B C D D  -
12 20 F 1 12  -  -  -  - A B B C C D  -
13 31 M 1 5  -  -  +  + A B C C D E  -
14 27 F 1 3  -  -  +  + A A B B C E  -
15 16 M 2 8  +  -  +  + A A B B C C  -
16 13 F 1 4  -  -  -  + A B C C D E  - 
17 7 F 1 12  + PA  +  + A A A A A A  -
18 14 M 3 15  -  -  -  - A A A A B B EDEMA
19 19 M 2 1  -  -  +  + A A B C C D  -
20 15 M 1 2  -  -  +  + A A B C D E  -
21 17 F 2 1  -  -  -  + A B B C C E  -
22 30 F 1 0.5  -  -  +  + A A B C C D  -
23 40 M 3 12  - CU  +  + A A B B C C  -
24 34 F 4 10  - AR  -  + A A A A A A ERYTHEMA
25 22 M 2 2  -  -  +  + A B B C C D  -
TABLE  2 - CRYOTHERAPY
PROFILE  OF THE   PATIENTS                         RESPONSE
S/NO AGE SEX
NO OF 
PATCHES
DURATION 
(MONTHS)
ATOPY - 
FAMILY
ATOPY-- 
PERSONAL
COUDABLI
TY SIGN
EXCLAMA
TION HAIR
2WKS 4 WKS 6WKS 8WKS 10WKS 12WKS DVERE EFFECTS
1 19 M 1 3  - AR  +  + A A A B B B  -
2 23 M 1 1  +  -  -  + A A B B C C  -
3 26 F 1 0.5  -  -  +  + A B B C D E  -
4 33 M 2 3  -  -  +  + A B B C C D  -
5 36 F 1 12  + CU  -  - A A A A A A  -
6 31 M 3 18  -  -  +  + A A A B B B
HYPOPIGMENTA
TION
7 29 F 2 9  -  -  +  + A A B B C C  -
8 41 M 1 4  -  -  -  + A A B B C D  -
9 38 M 3 24  -  -  -  - A A A A A A
HYPOPIGMENTA
TION
10 37 M 4 5  -  -  +  + A A A A A A ERYTHEMA
11 19 F 3 6  -  -  +  + A A A A B B  -
12 27 F 2 8  -  -  +  + A B B C C D  -
13 28 M 2 12  -  -  -  + A A A A B B  -
14 40 M 3 15  -  -  +  - A A A A A A MILD ATROPHY
15 36 M 2 10  - CU  +  + A A A A A A  -
16 34 F 1 2  -  -  +  + A A B C C D  -
17 23 F 2 6  -  -  +  + A B B C C D  -
18 28 M 2 7  -  -  +  + A A B B C C  -
19 29 F 1 1  +  -  -  + A A B C D E  -
20 19 M 2 12  - AD  +  - A A A A B B
HYPOPIGMENTA
TION
21 31 F 2 9  -  -  +  + A A A B B B  -
22 37 M 2 2  -  -  +  + A A B C C D  -
23 29 M 1 3  -  -  +  - A A B C C E  -
24 27 F 1 5  -  -  -  + A B C C D E
HYPERPIGMENT
ATION
25 27 F 1 6  -  -  +  + A A A A B B  -
        RESPONSE
TABLE    3 PHENOL
 PROFILE    OF    THE       PATIENTS
S/NO AGE SEX
NO OF 
PATCHES
DURATION(
MONTHS)
ATOPY -
FAMILY
ATOPY -
PERSONAL
COUDABLI
TY SIGN
EXCLAMA
TION HAIR
2WKS 4WKS 6WKS 8WKS 10WKS 12WKS
ADVERSE 
EFFECTS
1 27 M 4 1  -  CU  -  + A A A B B B ERYTHEMA
2 29 F 2 1  +  -  +  - A A B B C C
3 21 M 2 2  -  -  +  + A A A A B B
4 22 F 1 0.5  -  -  +  + A A B C D E
5 28 M 2 6  -  -  +  + A A A B B B
6 36 M 2 2  -  -  -  - A B B C C C
7 28 M 8 4  -  -  +  + A A A A A A
8 21 F 2 2.5  -  -  +  + A A A B B B ERYTHEMA
9 23 M 1 3  -  -  +  + A B B C C D
10 19 M 1 1  -  -  -  + A A A B B B
11 16 F 2 1  -  -  +  + A A B B B B
12 32 M 1 1.5  - CU  +  + A A A A A A
13 30 M 3 2  -  -  +  + A A B B B B
BURNING 
SENSATION
14 27 F 2 12  -  -  +   + A B B B B B
15 23 F 2 7  -  -  +  + A B B C C C
16 29 M 2 9  -  -  +   + A A A A A A
17 28 M 4 15  -  -  -  + A A B B B B
18 31 M 1 5  -  -  +  - A A B B C D
19 34 F 1 3  +  -  -  + A A A A A A
20 20 M 1 1  - AR  +  + A A A B B B
21 27 M 2 5  -  -  +  + A A B B B B
22 37 F 1 3  -  -  +  + A B B C C D
23 25 M 2 5  -  -  +  + A A A A A A
24 19 M 2 3  -  -  -  + A B B C C D
25 12 F 2 5  -  -  +  - A A B C D E
       PROFILE OF   THE    PATIENTS   RESPONSE
          TABLE 4 PHOTOTHERAPY
PROFORMA 
 
“COMPARISION OF VARIOUS TREATMENT MODALITIES IN PATIENTS 
WITH ALOPECIA AREATA” 
 
Name   :       Age /  Sex : 
OP /  IP No. :       Occupation 
Address : 
 
Chief Complaints: 
Loss of hair – duration 
Pruritis 
Others (specify) 
 
Past History: 
 H/o Similar complaints in the past 
 H/o Hypertension, Diabetes, Asthma, Epilepsy 
 
Personal History: 
 Type of Diet 
 Childhood eczema 
 Thyroid disease 
 Septic foci (ENT, dental , others) 
 
Family history: 
 Diabetes mellitus 
 Hypertension 
 Atopy 
 Other endocrine disorders 
 Other autoimmune disorders 
General Examination: 
 Pallor, Icterus, Clubbing, Cyanosis, Pedal edema, Lymphadenopathy 
 
Systemic Examination: 
 CVS, RS, P/A, CNS 
 Pulse 
 BP 
Dermatological Examination: 
 
 Examination  of patches : 
                                Size 
Shape 
Number 
Location 
                                Presence of white hair 
 
 Coudablity sign 
 Exclamation mark hair 
 Nail changes 
     Pitting 
     Others (specify) 
 Associated changes 
     Vitiligo 
     Other dermatoses (Specify) 
 Oral mucosa 
 Palms & Soles 
 Genitalia 
 Eyes 
Investigation: 
 CBC 
 LFT 
 RFT 
 VCTC 
 VDRL 
 Thyroid Function Test 
 KOH smear 
 
Therapy given: 
 Duration  of treatment 
 Clinical response 
 Adverse effects 
  
INFORMATION SHEET 
 
 
TITLE: “COMPARISION OF VARIOUS TREATMENT MODALITIES IN 
PATIENTS WITH ALOPECIA AREATA” 
 
Investigators    :  Dr. S. FATHIMA 
 
Name of the Participant      Age :  Sex : 
 
Study Setting   : Department of Dermatology 
Madras Medical College & RGGGH, 
Chennai – 3. 
 
 You are invited to take part in this study. The information in this document is 
meant to help you decide whether or not to take part. Please feel free to ask if you 
have any queries or concerns. 
 We are conducting a study on“COMPARISION OF VARIOUS TREATMENT 
MODALITIES IN PATIENTS WITH ALOPECIA AREATA” 
 This study will not affect your treatment. 
 Patients are randomly selected and divided into four groups.(A,B,C,D) of 25 
patients in each. 
 Group A – Treated with intralesional steroid (triamcinolone acetonide) 
 Group B – Treated with cryotherapy ( liquid nitrogen) 
 Group C – Treated with topical phenol ( 88%) 
 Group D – Treated with phototherapy( NBUVB) 
 The privacy of the patients in the research will be maintained throughout the 
study. In the event of any publication or presentation resulting from the research, 
no personally identifiable information will be shared. 
 Taking part in this study is voluntary. You are free to decide whether to 
participate in this study or to withdraw at any time; your decision will not result in 
any loss of benefits to which you are otherwise entitled. 
 The results of the special study may be intimated to you at the end of the study 
period or during the study if anything is found abnormal which may aid in the 
management or treatment. 
 
 
Signature of investigator     Signature of participant 
 
Dr. S. Fathima 
 
Date:        Date: 
  
 
INFORMED CONSENT FORM 
 
Title of the study :“COMPARISION OF VARIOUS TREATMENT MODALITIES 
IN PATIENTS WITH ALOPECIA AREATA” 
 
Name of the Participant :  
 
Name of the Principal (Investigator) : Dr. S. Fathima 
 
Name of the Institution : Department of Dermatology & Leprosy, Rajiv  
     Gandhi Govt. General Hospital, Chennai. 
 
Documentation of the informed consent 
I _____________________________ have read it has been read for me, the information 
in this form. I was free to ask any questions and they have been answered. I am over 18 
years of age and exercising my free power of choice, hereby give my consent to be 
included as a participant in the study. 
 
1. I have read and understood this consent form and the information provided to me. 
2. I have had the consent document explained in detail to me. 
3. I have been explained about the nature of the study. 
4. My rights and responsibilities have been explained to me by the investigator.  
5. I agree to cooperate with the investigator and I will inform her immediately if I suffer 
from unusual symptoms. 
6. I have not participated in any research study at any time. 
7. I am aware of the fact that I can opt out of the study at any time without having to 
give any reason and this will not affect my future treatment in this hospital. 
8. I hereby give permission to the investigators to release the information obtained from 
me as a result of participation in this study to the regulatory authorities, government 
agencies, and Institutional Ethics Committee. I understand that they are publicly 
presented. 
9. My identity will be kept confidential if my data are publicly presented. 
10. I am aware that if I have any question during this study, I should contact the 
investigator.  
 
Participant’s Initials :______________ 
 
For adult participants: 
Name and signature / thumb impression of the participant (or legal representative if 
participant incompetent) 
Name____________________ Signature_________________ Date_____________ 
Name and Signature of impartial witness (required for illiterate patients): 
Name ____________________ Signature_________________ Date_____________ 
Address and contact number of the impartial witness: 
Name and Signature of the investigator or his representative obtaining consent: 
Name ____________________ Signature_________________ Date_____________
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